MedPath

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

Phase 3
Completed
Conditions
Breast Cancer
Registration Number
NCT00381901
Lead Sponsor
National Cancer Institute, France
Brief Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving trastuzumab for 6 months is as effective as giving trastuzumab for 1 year in treating patients with breast cancer.

PURPOSE: This randomized phase III trial is studying trastuzumab to see how well it works when given for 6 months compared to 12 months in treating women with nonmetastatic breast cancer that can be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

* Compare the disease-free survival of women with nonmetastatic, resectable breast cancer treated with adjuvant trastuzumab (Herceptin®) for 6 months vs 12 months.

Secondary

* Compare cardiotoxicity in patients receiving these regimens.

* Compare the cardiotoxicity and disease-free survival of patients receiving concurrent trastuzumab and chemotherapy vs sequential administration.

* Correlate HER-2 polymorphism with disease-free survival/cardiotoxicity in these patients.

OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified according to participating center, modality of adjuvant chemotherapy (concurrent vs sequential), and adjuvant hormonal therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.

* Arm I (control arm, 12-month therapy): Patients continue to receive trastuzumab (Herceptin®) IV until a total of 12 months of therapy is completed in the absence of disease progression or unacceptable toxicity.

* Arm II (experimental arm, 6-month therapy): Patients continue to receive trastuzumab\* IV until a total of 6 months of therapy is completed in the absence of disease progression or unacceptable toxicity.

NOTE: \*Patients who have already finished 6 months of trastuzumab at randomization do not receive further trastuzumab.

Some patients undergo blood collection for HER-2 polymorphism analysis.

After completion of study therapy, patients are followed periodically for approximately 5 years.

PROJECTED ACCRUAL: A total of 7,000 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
3400
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to recurrence
Secondary Outcome Measures
NameTimeMethod
Cardiotoxicity as measured by LVEF
Distant metastasis-free survival
Overall survival

Trial Locations

Locations (81)

C.H.U. de Brest

🇫🇷

Brest, France

Hopital Louis Pasteur

🇫🇷

Colmar, France

Centre Hospital Regional Universitaire de Limoges

🇫🇷

Limoges, France

Centre Paul Papin

🇫🇷

Angers, France

C.H.G. Beauvais

🇫🇷

Beauvais, France

Centre Hospitalier General

🇫🇷

Brive, France

Clinique Notre Dame du Bon Secours

🇫🇷

Chartres, France

Centre de Lutte Contre le Cancer Georges-Francois Leclerc

🇫🇷

Dijon, France

Clinique Sainte-Marguerite

🇫🇷

Hyeres, France

Centre De Radiotherapie Charlebourg

🇫🇷

La Garenne Colombes, France

Centre Jean Perrin

🇫🇷

Clermont-Ferrand, France

Hopital Edouard Herriot - Lyon

🇫🇷

Lyon, France

Centre Hospitalier Departemental

🇫🇷

La Roche Sur Yon, France

Hopital Andre Mignot

🇫🇷

Le Chesnay, France

Hopital Clinique Claude Bernard

🇫🇷

Metz, France

Centre de Radiologie et de Traitement des Tumeurs

🇫🇷

Meudon La Foret, France

Centre Hospitalier de Montelimar

🇫🇷

Montelimar, France

Clinique Les Genets

🇫🇷

Narbonne, France

Centre Antoine Lacassagne

🇫🇷

Nice, France

Centre Hospitalier Intercommunal de Poissy

🇫🇷

Poissy, France

Centre Hospitalier La Fontonne

🇫🇷

Antibes, France

Institut Sainte Catherine

🇫🇷

Avignon, France

Centre Hospitalier Victor Dupouy

🇫🇷

Argenteuil, France

Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz

🇫🇷

Besancon, France

Hopital Avicenne

🇫🇷

Bobigny, France

Institut Bergonie

🇫🇷

Bordeaux, France

Polyclinique Bordeaux Nord Aquitaine

🇫🇷

Bordeaux, France

Clinique Tivoli

🇫🇷

Bordeaux, France

Centre Hospitalier Docteur Duchenne

🇫🇷

Boulogne Sur Mer, France

Clinique Victor Hugo

🇫🇷

Le Mans, France

Centre Hospitalier de Montlucon

🇫🇷

Montlucon, France

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

🇫🇷

Montpellier, France

Centre Azureen de Cancerologie

🇫🇷

Mougins, France

Centre Catherine de Sienne

🇫🇷

Nantes, France

Clinique Hartmann

🇫🇷

Neuilly sur Seine, France

Clinique Belvedere

🇫🇷

Nice, France

Clinique Saint George

🇫🇷

Nice, France

C.H.U. de Nimes - Groupe Hospitals-Universitaire Caremeau

🇫🇷

Nimes, France

Clinique De Valdegour

🇫🇷

Nimes, France

Hopital Europeen Georges Pompidou

🇫🇷

Paris, France

Institut Curie Hopital

🇫🇷

Paris, France

Hopital Saint-Louis

🇫🇷

Paris, France

CHU Pitie-Salpetriere

🇫🇷

Paris, France

Polyclinique Francheville

🇫🇷

Perigueux, France

Clinique Saint - Pierre

🇫🇷

Perpignan, France

Centre Hospitalier Lyon Sud

🇫🇷

Pierre Benite, France

Institut Jean Godinot

🇫🇷

Reims, France

Hopital Jean Bernard

🇫🇷

Poitiers, France

Centre Eugene Marquis

🇫🇷

Rennes, France

CHG Roanne

🇫🇷

Roanne, France

Clinique Armoricaine De Radiologie

🇫🇷

Saint Brieuc, France

Centre Henri Becquerel

🇫🇷

Rouen, France

Institut de Cancerologie de la Loire

🇫🇷

Saint Priest en Jarez, France

Centre Etienne Dolet

🇫🇷

Saint-Nazaire, France

Clinique Sainte Clotilde

🇫🇷

Sainte Clotilde, France

Clinique de l'Orangerie

🇫🇷

Strasbourg, France

Centre Paul Strauss

🇫🇷

Strasbourg, France

Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer

🇫🇷

Toulon - Cedex, France

Institut Claudius Regaud

🇫🇷

Toulouse, France

Centre Hospitalier Universitaire Bretonneau de Tours

🇫🇷

Tours, France

Hopital Jean Monnet

🇫🇷

Epinal, France

Centre Hospitalier d'Annecy

🇫🇷

Annecy, France

Centre Hospitalier de Dax

🇫🇷

Dax, France

Centre de Radiotherapie et Oncologie Saint-Faron

🇫🇷

Mareuil Les Meaux, France

Hopital Clarac

🇫🇷

Fort de France Cedex, France

Institut d'Oncologie Hartmann

🇫🇷

Levallois-Perret, France

Hopital Robert Boulin

🇫🇷

Libourne, France

Clinique Chenieux

🇫🇷

Limoges, France

Centre Hospitalier General de Mont de Marsan

🇫🇷

Mont-de-Marsan, France

Centre Medical Parot

🇫🇷

Lyon, France

Centre Hospitalier William Morey

🇫🇷

Chalon-sur-Saone, France

Centre Leon Berard

🇫🇷

Lyon, France

Centre Hospital General Robert Ballanger

🇫🇷

Aulnay Sous Bois, France

Institut Prive de Cancerologie

🇫🇷

Grenoble, France

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes

🇫🇷

Marseille, France

Clinique Clementville

🇫🇷

Montpellier, France

Hopital Antoine Beclere

🇫🇷

Clamart, France

Centre Hospitalier de Lagny

🇫🇷

Lagny Sur Marne, France

CH Meulan

🇫🇷

Meulan, France

Centre Regional Rene Gauducheau

🇫🇷

Nantes-Saint-Herblain, France

Centre Hospitalier - Pau

🇫🇷

Pau, France

© Copyright 2025. All Rights Reserved by MedPath